Display options
Share it on

Pharmacoeconomics. 2017 Jun;35(6):607-612. doi: 10.1007/s40273-017-0499-z.

How Qualitative Methods Can be Used to Inform Model Development.

PharmacoEconomics

Samantha Husbands, Susan Jowett, Pelham Barton, Joanna Coast

Affiliations

  1. School of Social and Community Medicine, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol, BS8 2PS, UK. [email protected].
  2. Health Economics Unit, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
  3. School of Social and Community Medicine, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol, BS8 2PS, UK.

PMID: 28321640 DOI: 10.1007/s40273-017-0499-z

Abstract

Decision-analytic models play a key role in informing healthcare resource allocation decisions. However, there are ongoing concerns with the credibility of models. Modelling methods guidance can encourage good practice within model development, but its value is dependent on its ability to address the areas that modellers find most challenging. Further, it is important that modelling methods and related guidance are continually updated in light of any new approaches that could potentially enhance model credibility. The objective of this article was to highlight the ways in which qualitative methods have been used and recommended to inform decision-analytic model development and enhance modelling practices. With reference to the literature, the article discusses two key ways in which qualitative methods can be, and have been, applied. The first approach involves using qualitative methods to understand and inform general and future processes of model development, and the second, using qualitative techniques to directly inform the development of individual models. The literature suggests that qualitative methods can improve the validity and credibility of modelling processes by providing a means to understand existing modelling approaches that identifies where problems are occurring and further guidance is needed. It can also be applied within model development to facilitate the input of experts to structural development. We recommend that current and future model development would benefit from the greater integration of qualitative methods, specifically by studying 'real' modelling processes, and by developing recommendations around how qualitative methods can be adopted within everyday modelling practice.

References

  1. Pharmacoeconomics. 2016 Nov;34(11):1161-1172 - PubMed
  2. BMJ. 2011 Apr 11;342:d1766 - PubMed
  3. Health Econ. 2006 Jul;15(7):677-87 - PubMed
  4. Lancet. 2001 Aug 11;358(9280):483-8 - PubMed
  5. Value Health. 2015 Jun;18(4):512-29 - PubMed
  6. Pharmacoeconomics. 2006;24(4):355-71 - PubMed
  7. Health Econ. 1999 Jun;8(4):345-53 - PubMed
  8. Pharmacoeconomics. 2011 Jun;29(6):455-9 - PubMed
  9. Int J Technol Assess Health Care. 2014 Jul;30(3):333-40 - PubMed
  10. Value Health. 2012 Sep-Oct;15(6):804-11 - PubMed
  11. Appl Health Econ Health Policy. 2016 Apr;14 (2):129-33 - PubMed
  12. BMJ. 1995 Jul 29;311(7000):299-302 - PubMed
  13. Value Health. 2013 Jul-Aug;16(5):830-6 - PubMed
  14. Health Technol Assess. 2010 May;14(25):iii-iv, ix-xii, 1-107 - PubMed
  15. J Adv Nurs. 2003 Feb;41(4):376-82 - PubMed
  16. J Adv Nurs. 2000 Oct;32(4):1008-15 - PubMed
  17. Value Health. 2012 Sep-Oct;15(6):796-803 - PubMed
  18. BMJ. 2000 Jan 1;320(7226):50-2 - PubMed
  19. BMJ. 1995 Aug 5;311(7001):376-80 - PubMed
  20. Health Econ. 2013 Mar;22(3):253-7 - PubMed
  21. Value Health. 2016 Jul-Aug;19(5):588-601 - PubMed
  22. BMJ Open. 2012 Feb 08;2:e000562 - PubMed

MeSH terms

Publication Types